4D Molecular Therapeutics, Inc. Capital Expenditures
4D Molecular Therapeutics, Inc. (FDMT) reported Capital Expenditures of $55.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was -$70.00K, a 107.38% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was -$91.00K, a 105.12% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $66.00K, a 81.09% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $631.00K, a 11.13% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $536.00K, a 85.84% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $3.79M, a 36.63% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $2.77M, a 75.98% decline from fiscal 2022.
- 4D Molecular Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $11.54M, a 26.63% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $55.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$161.00K derived: sum of 2 quarters · filed 2026-03-18 | -$95.00K derived: sum of 3 quarters · filed 2026-08-13 | $536.00K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$25.00K derived: sum of 2 quarters · filed 2026-08-13 | $606.00K 10-Q · filed 2025-11-10 | $1.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $697.00K 10-Q · filed 2026-08-13 | $1.65M derived: sum of 3 quarters · filed 2026-08-13 | $3.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $631.00K 10-Q · filed 2025-05-08 | $1.58M derived: sum of 2 quarters · filed 2026-03-18 | $3.36M derived: sum of 3 quarters · filed 2026-03-18 | $3.71M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-12-31 | $949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.73M derived: sum of 2 quarters · filed 2026-03-18 | $3.08M derived: sum of 3 quarters · filed 2026-03-18 | $3.79M 10-K · filed 2026-03-18 |
| 2024-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.13M derived: sum of 2 quarters · filed 2025-11-10 | $2.84M 10-Q · filed 2025-11-10 | $3.39M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.06M 10-Q · filed 2025-08-11 | $1.61M derived: sum of 3 quarters · filed 2025-08-11 | $2.01M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $710.00K 10-Q · filed 2025-05-08 | $1.26M derived: sum of 2 quarters · filed 2025-05-08 | $1.66M derived: sum of 3 quarters · filed 2025-05-08 | $2.47M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $954.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.76M derived: sum of 3 quarters · filed 2025-02-28 | $2.77M 10-K · filed 2025-02-28 |
| 2023-09-30 | $405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.21M derived: sum of 2 quarters · filed 2024-11-13 | $2.22M 10-Q · filed 2024-11-13 | $3.31M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $805.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.82M 10-Q · filed 2024-08-08 | $2.91M derived: sum of 3 quarters · filed 2024-08-08 | $4.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.01M 10-Q · filed 2024-05-09 | $2.10M derived: sum of 2 quarters · filed 2024-05-09 | $4.07M derived: sum of 3 quarters · filed 2024-05-09 | $6.13M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.06M derived: sum of 2 quarters · filed 2024-02-29 | $5.12M derived: sum of 3 quarters · filed 2024-02-29 | $11.54M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.03M derived: sum of 2 quarters · filed 2023-11-09 | $10.44M 10-Q · filed 2023-11-09 | $15.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $8.48M 10-Q · filed 2023-08-09 | $13.57M derived: sum of 3 quarters · filed 2023-08-09 | $16.21M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $6.41M 10-Q · filed 2023-05-11 | $11.51M derived: sum of 2 quarters · filed 2023-05-11 | $14.14M derived: sum of 3 quarters · filed 2023-05-11 | $14.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.73M derived: sum of 2 quarters · filed 2023-03-15 | $8.47M derived: sum of 3 quarters · filed 2023-03-15 | $9.11M 10-K · filed 2023-03-15 |
| 2021-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.37M derived: sum of 2 quarters · filed 2022-11-08 | $4.01M 10-Q · filed 2022-11-08 | $4.52M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $737.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.38M 10-Q · filed 2022-08-11 | $1.89M derived: sum of 3 quarters · filed 2022-08-11 | $1.54M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $642.00K 10-Q · filed 2022-05-12 | $1.15M derived: sum of 2 quarters · filed 2022-05-12 | $801.00K derived: sum of 3 quarters · filed 2022-05-12 | $921.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $508.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $159.00K derived: sum of 2 quarters · filed 2022-03-28 | $279.00K derived: sum of 3 quarters · filed 2022-03-28 | $1.00M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$229.00K derived: sum of 2 quarters · filed 2021-11-10 | $492.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $841.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $721.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $3.20M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |